Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Induced pluripotent stem cell based allogeneic cell therapy - LIfT BioSciences

Next Previous
Drug Profile

Induced pluripotent stem cell based allogeneic cell therapy - LIfT BioSciences

Alternative Names: IMAN (iPSC) - LIfT BioSciences; iN-LIfT; Induced pluripotent stem cell derived neutrophil based leukocyte infusion therapy - LIfT Biosciences

Latest Information Update: 19 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LIfT Biosciences
  • Developer Kings College London; LIfT Biosciences
  • Class Antineoplastics; Immunotherapies; Induced pluripotent stem cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Neutrophil replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 19 Jan 2026 Early research phase development is ongoing in Solid tumours in United Kingdom (Parenteral)
  • 28 Apr 2024 No recent reports of development identified for research development in Solid-tumours in United Kingdom (Parenteral, Infusion)
  • 06 Jan 2023 LIfT Biosciences plans to file an IND application for Solid tumours in the second half of 2024 (LIfT Biosciences pipeline, January 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top